Journal of Chemotherapy最新文献_第5页

Comparison of Syrian generic ceftriaxone sodium preparations for injection: BHT content and its implications. 叙利亚普通注射用头孢曲松钠制剂的比较：BHT含量及其意义。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-21 DOI: 10.1080/1120009X.2025.2468046

Abeer Srour, Khawla Alamere, Ghassan Abo Chameh, Basima Arous, Mohammad Amer Al-Mardini

{"title":"Comparison of Syrian generic ceftriaxone sodium preparations for injection: BHT content and its implications.","authors":"Abeer Srour, Khawla Alamere, Ghassan Abo Chameh, Basima Arous, Mohammad Amer Al-Mardini","doi":"10.1080/1120009X.2025.2468046","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2468046","url":null,"abstract":"This study aimed to evaluate the compatibility of generic ceftriaxone sodium preparations with various rubber closures used in pharmaceutical packaging, focusing on the release of butylated hydroxytoluene (BHT), an antioxidant present in rubber closures that may migrate into drug products. BHT levels were quantified using gas chromatography-mass spectrometry (GC-MS) to assess stability and safety. Results showed that all samples contained BHT, with concentrations ranging from below the quantification limit to a maximum of 5.65 ppm. Notably, 47.62% of the samples exceeded the threshold of toxicological concern (TTC) of 1.5 µg/day, raising significant safety concerns. Older samples exhibited higher BHT levels, and products from pharmacies generally had greater concentrations than those obtained from manufacturers. These findings underscore the critical importance of assessing interactions between drug formulations and packaging materials, emphasizing the need for rigorous quality control in injectable pharmaceuticals. Future research should explore strategies to mitigate BHT accumulation in these preparations.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment with oxaliplatin and programmed cell death protein 1 inhibitor in recurrent advanced endometrial carcinoma with mismatch repair defects: a case report and literature review. 奥沙利铂联合程序性细胞死亡蛋白1抑制剂成功治疗复发性晚期子宫内膜癌伴错配修复缺陷1例报告及文献复习

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-21 DOI: 10.1080/1120009X.2025.2466274

Jian Qiu, Tian Ding, Mingyue Cao, Xiaohong Huang, Yinfeng Wang

引用次数: 0

Investigation of chemotherapy-induced cardiac dysfunction in breast cancer. 乳腺癌化疗诱发心功能障碍的研究。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-20 DOI: 10.1080/1120009X.2025.2466278

Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath

{"title":"Investigation of chemotherapy-induced cardiac dysfunction in breast cancer.","authors":"Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath","doi":"10.1080/1120009X.2025.2466278","DOIUrl":"10.1080/1120009X.2025.2466278","url":null,"abstract":"Although recent advancements in cancer treatment have significantly improved survival rates, they have also raised concerns regarding severe adverse effects, including cardiotoxicity. We conducted a prospective study at Dayanand Medical College and Hospital, Ludhiana to assess chemotherapy-related cardiac dysfunction in newly diagnosed, histologically confirmed breast cancer cases. Among 97 breast cancer patients undergoing chemotherapy, 13 (13.4%) developed left ventricular dysfunction (LVD), predominantly in younger patients with left-sided breast involvement (64.9%). A significant association was found between estrogen receptor (ER) positivity and LVD risk (P = 0.03), with 15.4% of LVD patients also being hypertensive. The incidence of LVD was notably high at 38.5% among patients receiving trastuzumab, while cumulative doses of doxorubicin and cyclophosphamide did not show significant correlation with LVD. Recovery was promising, with 76.9% of affected patients demonstrating significant improvement post-treatment. These findings highlight the need for continuous cardiac monitoring and personalized treatment strategies to mitigate LVD risk.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab associated immune thrombocytopenia. 派姆单抗相关的免疫性血小板减少症。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-19 DOI: 10.1080/1120009X.2025.2468045

Perihan Perkin, Serhat Sekmek, Dogan Bayram, Fahriye Tugba Kos

引用次数: 0

Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors. SARS-CoV-2感染对恶性血液肿瘤患者临床特征、抗体水平和免疫反应的影响

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-13 DOI: 10.1080/1120009X.2025.2458377

Yan Li, Jing Zhang, Xiang Wang, Yan Wang, Ruili Wang, Yongzhen Chen, Changkai Chen, Yuyang Tian

{"title":"Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors.","authors":"Yan Li, Jing Zhang, Xiang Wang, Yan Wang, Ruili Wang, Yongzhen Chen, Changkai Chen, Yuyang Tian","doi":"10.1080/1120009X.2025.2458377","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2458377","url":null,"abstract":"This study evaluated SARS-CoV-2 infection impacts on clinical characteristics, antibody levels, and immune responses in 100 malignant hematological tumor patients. Laboratory assessments included hematological, biochemical, and inflammatory markers. Multivariable analysis identified age (OR = 1.56, p = 0.004), chemotherapy cycles (OR = 1.86, p < 0.001), comorbidities (OR = 3.15, p = 0.015), WBC count (OR = 1.79, p = 0.016), CRP (OR = 2.07, p = 0.007), ferritin (OR = 1.22, p = 0.035), IL-6 (OR = 1.59, p = 0.001), IgG (OR = 2.28, p = 0.037), CD8+ T cells (OR = 2.97, p = 0.005), and NK cells (OR = 0.80, p = 0.019) as COVID-19 risk factors. COVID-19 patients showed significantly higher hospitalization (30.77% vs 10.42%, p = 0.007), ICU admission (23.08% vs 6.25%, p = 0.019), and lower 1-year survival (59.62% vs 87.50%, p = 0.002) versus controls. SARS-CoV-2 infection induces hematological/immune alterations and worsens clinical outcomes in hematological malignancy patients, emphasizing their heightened vulnerability.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets. 通过抗pd -1单药治疗黑色素瘤获得的基因面板揭示了预后标志物和治疗靶点。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-13 DOI: 10.1080/1120009X.2025.2465013

Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang

{"title":"The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets.","authors":"Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang","doi":"10.1080/1120009X.2025.2465013","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2465013","url":null,"abstract":"To search for key drug resistance biomarkers and potential chemotherapeutic agents for combination therapy in melanoma patients. The common up-regulated differentially expressed genes were acquired from two cohort studies, GSE91061 and PRJEB23709. Univariate and multivariate Cox regression survival analyses were performed to screen for important prognostic biomarkers. A multi-gene panel including APP, ARHGAP42, GSTA4 and UCHL1, not only plays an important role in prognostic indicators, but also in predicting the probability of resistance to anti-PD-1 in patients with melanoma. Chemotherapy drug response models found five potential drugs, including all-trans retinoic acid, doxorubicin, etoposide, methotrexate and MG-132, were significantly associated with target genes in gene-panel. Molecular docking confirmed that potential drugs have good binding ability to target genes APP, GSTA4 and UCHL1, suggesting that the multi-gene panel is expected to provide assistance for drug resistance prediction and prognosis assessment and combination therapy in patients with anti-PD-1 resistant melanoma.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":1.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness and safety of meropenem-vaborbactam in the treatment of carbapenem-resistant enterobacterales (CRE) infections: a systematic review and meta-analysis. 美罗培烯-瓦博巴坦治疗碳青霉烯耐药肠杆菌（CRE）感染的实际有效性和安全性：一项系统综述和荟萃分析。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-13 DOI: 10.1080/1120009X.2025.2465129

Dongcai Jin, Danyang Hu, Yuhong Jin

{"title":"Real-world effectiveness and safety of meropenem-vaborbactam in the treatment of carbapenem-resistant enterobacterales (CRE) infections: a systematic review and meta-analysis.","authors":"Dongcai Jin, Danyang Hu, Yuhong Jin","doi":"10.1080/1120009X.2025.2465129","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2465129","url":null,"abstract":"This study aimed to evaluate the effectiveness and safety of Meropenem-Vaborbactam(M-V) for treating carbapenem-resistant Enterobacterales (CRE) infections based on real-world data. A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was conducted, considering studies up to October 31, 2024. Real-world evidence from registries and nonselected case series involving 10 or more adult patients treated with Meropenem-Vaborbactam for CRE infections was included. Meta-analyses using a random-effects model were performed, with the primary outcomes being clinical efficacy and survival, including 30-day and 90-day survival rates. Out of 1862 potentially relevant publications, six studies were included in the meta-analysis. The pooled clinical success rate was 75% (95% CI, 66%-82%), and the pooled 30-day and 90-day survival rates were 75% (95% CI, 71%-78%) and 69% (95% CI, 61%-76%), respectively. Importantly, no serious adverse effects were reported. In conclusion, Meropenem-Vaborbactam demonstrated both efficacy and safety in treating CRE infections in real-world settings. This study was registered with PROSPERO (CRD42022370880).","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The tumor microenvironment: shaping cancer progression and treatment response. 肿瘤微环境：影响癌症进展和治疗反应。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-01-05 DOI: 10.1080/1120009X.2023.2300224

Sharav A Desai, Vipul P Patel, Kunal P Bhosle, Sandip D Nagare, Kirti C Thombare

{"title":"The tumor microenvironment: shaping cancer progression and treatment response.","authors":"Sharav A Desai, Vipul P Patel, Kunal P Bhosle, Sandip D Nagare, Kirti C Thombare","doi":"10.1080/1120009X.2023.2300224","DOIUrl":"10.1080/1120009X.2023.2300224","url":null,"abstract":"The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment response. It comprises a complex network of stromal cells, immune cells, extracellular matrix, and blood vessels, all of which interact with cancer cells and influence tumor behaviour. This review article provides an in-depth examination of the TME, focusing on stromal cells, blood vessels, signaling molecules, and ECM, along with commonly available therapeutic compounds that target these components. Moreover, we explore the TME as a novel strategy for discovering new anti-tumor drugs. The dynamic and adaptive nature of the TME offers opportunities for targeting specific cellular interactions and signaling pathways. We discuss emerging approaches, such as combination therapies that simultaneously target cancer cells and modulate the TME. Finally, we address the challenges and future prospects in targeting the TME. Overcoming drug resistance, improving drug delivery, and identifying new therapeutic targets within the TME are among the challenges discussed. We also highlight the potential of personalized medicine and the integration of emerging technologies, such as immunotherapy and nanotechnology, in TME-targeted therapies. This comprehensive review provides insights into the TME and its therapeutic implications. Understanding the TME's complexity and targeting its components offer promising avenues for the development of novel anti-tumor therapies and improved patient outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"15-44"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes. 乳腺癌亚型对新辅助化疗反应的预后影响。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-02-13 DOI: 10.1080/1120009X.2024.2314830

Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz

{"title":"Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.","authors":"Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz","doi":"10.1080/1120009X.2024.2314830","DOIUrl":"10.1080/1120009X.2024.2314830","url":null,"abstract":"The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to 2019, a total of 139 patients who were histologically confirmed to have breast cancer, underwent NAC, and subsequently received breast and axillary surgery, were retrospectively included in this study. The rates of pathological complete response (pCR) to NAC were significantly higher for HER2-positive and triple-negative subtypes than for luminal A and HER2-negative subtypes (p = 0.013). Multivariate analysis for disease-free survival (DFS) revealed that tumour grade and the presence of pCR were independent prognostic factors. The presence or absence of a pCR with NAC was an independent prognostic indicator in the multivariate analysis for overall survival (OS). Lastly, achieving a pCR was independently predicted by 18F-FDG PET/CT findings, the HER2-positive subtype, and the triple-negative subtype. Despite the inherent methodological limitations, our findings underscore the significance of identifying predictive markers to tailor NAC plans, with the aim of improving survival outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"60-68"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients. 以头孢唑肟/阿维菌素为基础和以磷霉素加美罗培南为基础的方案治疗重症患者耐碳青霉烯类肺炎克雷伯氏菌感染的比较研究。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-03 DOI: 10.1080/1120009X.2024.2349439

Uğur Önal, Ülkü Tüzemen, Pınar Küçükdemirci Kaya, Remzi İşçimen, Nermin Kelebek Girgin, Cüneyt Özakın, Ferda Kahveci, Halis Akalın

{"title":"A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients.","authors":"Uğur Önal, Ülkü Tüzemen, Pınar Küçükdemirci Kaya, Remzi İşçimen, Nermin Kelebek Girgin, Cüneyt Özakın, Ferda Kahveci, Halis Akalın","doi":"10.1080/1120009X.2024.2349439","DOIUrl":"10.1080/1120009X.2024.2349439","url":null,"abstract":"The main aim of this study was to compare and analyze the effectiveness of treatment regimens using ceftazidime/avibactam (CAZ/AVI) versus fosfomycin plus meropenem (FOS/MER) for managing bloodstream infections (BSI) or ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) in critically ill patients. Between 4 January 2019, and 16 July 2023, adult patients (≥18 years old) diagnosed with BSI or VAP due to culture confirmed CRKP in ICU of a tertiary care hospital were investigated retrospectively. A total of 71 patients were categorized into two groups: 30 patients in CAZ/AVI-based, and 41 patients in FOS/MER-based group. No substantial disparities were found in the total duration of ICU hospitalization, as well as the 14- and 30-day mortality rates, between patients treated with CAZ/AVI-based and FOS/MER-based therapeutic regimens. We consider that our study provides for the first time a comprehensive understanding of treatment outcomes and associated risk factors among patients with CRKP-related infections.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0